Novo’s REPAIR Fund: Application Template Out (15 May Deadline) + Sr. Associate Job Opening

Dear All:

The new Novo REPAIR impact fund ($165m over 5 years for antibacterials) is now open for applications — see the template at this link. Applications are due 15 May.

Relatedly, Novo would like to hire a Senior Associate to help manage the fund. Primary qualifications are (1) scientific understanding of microbiology or a related field (PhD preferred) and (2) at least one year’s investment experience in either venture investing or corporate business development. The position is based in Copenhagen. Inquiries should be made to Hanne Veitland (HVeitland@SpencerStuart.com). 

While you’re considering these opportunities, don’t forget that…

is one of these for you? I hope so! All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

How the sausage is made: A day of advocacy for PASTEUR

Dear All, Along with more than 50 others, I spent Tuesday 12 Sep 2023 on Capitol Hill visiting offices of members of Congress (Senate and House) seeking support for the PASTEUR Act. If you’re a regular reader, you’ll know that we now have substantial bipartisan support for PASTEUR: it was re-introduced as The Pioneering Antimicrobial

Canada says, “Let’s pull together!” in a major new report

Dear All (and with thanks to Kevin for co-authoring): Yesterday saw the release of a major new report on Pull incentives from Canada! The report’s cover art eloquently summarizes its key message: Well said … and proves that a picture really is worth 1,000 words! Here are the links you’ll need: The report’s webpage at the

€100m HERA Invest fund; Sign to support PASTEUR; Superb AMR movie!

Dear All,  Expanding the available Push funding, the EU’s HERA (Health Emergency Preparedness and Response Authority) has created HERA Invest by allocating €100m in support early and late phases of clinical trials. HERA Invest is open on a rolling application basis to EU-based SMEs developing medical countermeasures that address one of the following cross-border health threats: (i)

Scroll to Top